Our Team
Trusted. Driven. Skilled
We are radiopharmaceutical specialists
We are radiopharmaceutical specialists
Owen Roberts joined CPDC in October 2022 as CEO bringing over 20 years of biotech executive experience to his role at CPDC.
A serial biotech entrepreneur, Owen was most recently the founder and CEO of Nobelex Biotech Inc., a Canadian biotech contract research organization focused on discovering and developing antibiotics to treat bacterial infections caused by drug-resistant bacteria. In addition to leading Nobelex since 2014, Owen also held part-time senior management roles with Meta Inc. (as CFO from 2015-2016) and M4K Pharma (as CEO from 2017 to 2020).
Prior to founding Nobelex in 2014, Owen was a co-founder of Affinium Pharmaceuticals, a privately held venture funded, clinical stage, antibiotic company. At Affinium, Owen held the position of CFO and led the company’s finance and business development until the successful sale of Affinium’s antibiotic programs to Debiopharm International, S.A. in February 2014.
Prior to Affinium, in 1998, Owen helped create Borealis Biosciences, one of two companies which would merge to form Affinium in 2000. Prior to entering biotech, Owen was a financial executive at the Canadian subsidiaries of major US financial institutions.
Owen is a graduate of McGill University and is also a Chartered Financial Analyst.
Catherine Love joined CPDC in 2024 as Vice President, Business Development and Investments, bringing over 20 years life science and biotechnology experience to the company.
Prior to joining CPDC, Catherine held senior roles across Canada in sell-side equity research, venture capital and drug royalty investing, corporate investor relations & finance, and not-for-profit innovation organizations. As a member of CPDC’s leadership team, Catherine heads business development and investments, as well as the evaluation and execution of other strategic initiatives. Catherine holds a Bachelor of Science degree in biochemistry from McGill University, Master of Science degree in organic chemistry from the University of Toronto, and the Chartered Financial Analyst designation.
Oscar Grilli first joined CPDC in May 2019 as the Quality Assurance Director and returned in June 2024 in his current role, bringing over 20 years of managerial experience across pharmaceuticals, CMOs, vaccines, cosmetics, radiopharmaceuticals, and engineering firms.
He has successfully implemented GMP quality systems, validation programs for both existing and new facilities, routine monitoring programs, training programs, improvement initiatives, and hosting several regulatory inspections across multinational companies. His extensive experience also includes managing various Quality functions such as Quality Assurance, Quality Control, Sterility Assurance, Technology Transfer, and Analytical Development.
As a member of CPDC’s Leadership Team, Oscar provides strategic vision, leadership, and functional expertise, working closely with other key functional areas. His focus is on delivering Quality expertise and strategic guidance to CPDC, supporting the establishment and improvement of QMS for CPDC’s associated partners, and fostering the company’s business growth.
Oscar holds a bachelor’s degree in chemical engineering and is a licensed professional engineer in Ontario.
Martin Poirier joined CPDC in April 2025 as Vice President, Contract Research, bringing over 25 years of pharmaceutical industry experience to the company.
Prior to joining CPDC, Martin held senior leadership roles across North America working for various contract research organizations. Martin gained extensive experience leading cross-functional teams in several scientific disciplines such as bioanalysis, biomarkers, immunology and toxicology in all stages of drug development including discovery, research models, preclinical and clinical testing.
As a member of CPDC’s leadership team, Martin provides strategic vision, team leadership, scientific and operational management, and client engagement, working closely with other key functional areas. This role involves working directly with clients and CRO service partners to provide specialized support for research and preclinical radiotherapeutics and diagnostics development.
Martin is a graduate of INRS-Santé in Experimental Health Sciences.
Ruth Organ joined CPDC in 2023 as the Sr. Director, Controller, Finance and Administration. Ruth brings over 20 years of experience in strategic financial leadership roles across Canada from various industries, including communications, advertising & publishing, manufacturing and construction. Ruth has led diverse domestic and global teams in finance, accounting and regulatory, and multi year, company wide transformational projects and initiatives.
As a member of the leadership team, Ruth is responsible for the finance operations, HR, IT and administrative initiates as well as managing the financial aspects of various grant programs.
Ruth is a Chartered Professional Accountant and holds her undergraduate degree from University of Waterloo.
Holly Bilton joined CPDC in 2019, and currently holds the title of Associate Director, Business Development. In her current role, Dr. Bilton is responsible for leading and supporting initiatives in business development and is the current Executive Chair for the Canadian Medical Isotope Ecosystem (CMIE).
Holly has over 10 years’ experience in radiopharmaceutical development. Prior to joining CPDC, Holly obtained her PhD from McMaster University under Dr. John Valliant, focusing on the discovery and development of radiopharmaceuticals and multimodal imaging probes.
Meenalochani Sivasubramanian joined CPDC in December 2022 as the Associate Director, Clinical Programs. In her current role, Dr. Sivasubramanian manages the PSMA 1007 clinical program at CPDC.
Dr. Sivasubramanian has a PhD in Neuroscience from the National University of Singapore and over 8 years of experience as a postdoctoral fellow working on various neurodegenerative and neuropsychiatric disorders of the brain, elucidating pathophysiologic mechanisms and potential treatment strategies for drug addictions, schizophrenia, Huntington Disease and Parkinson’s disease. Prior to joining here Meena worked as a Program Manager managing the operations of the Slaight Family Centre for Advanced MRI at UHN.
Mohamed Mohammad joined CPDC in 2024 as Manager, Business Development. Mohamed graduated from McMaster University with a Master’s in Biomedical Discovery and Commercialization, and has dedicated his career to working with nonprofit organizations.
In addition to business development, Mohamed plays a supporting role for the Canadian Medical Isotope Ecosystem (CMIE). Mohamed has a strong foundation in both the science and business aspects of the Biotech sector. In his role, he aims to drive growth and foster strategic partnerships to drive the goal of making nuclear medicine available for all Canadians.
Mansura Mustary joined CPDC in 2025 and currently holds the position of Manager, GMP Support (Quality Operations). She brings over a decade of experience in the pharmaceutical and radiopharmaceutical industries, with specialized expertise in sterility assurance, regulatory compliance, and quality operations. Her background includes more than eight years in management roles, with additional strengths in audit management, quality investigations, validation, and technology transfer.
As a key member of CPDC’s Quality Team, Mansura provides technical assistance on GMP and Quality Assurance to various radiopharmaceutical manufacturing sites across Canada with the objectives to help them develop and enhance their level of GMP compliance to meet regulatory expectations.
Mansura holds an Honors Bachelor of Science in Biology with a minor in Mathematics from the University of Toronto. She also earned a diploma in Chemical Laboratory Technology and a graduate certificate in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College, and pursuing Quality Auditor certification through the American Society for Quality (ASQ), reflecting her commitment to ongoing professional development.
Zainab Ahmad joined CPDC in 2022, and currently holds the title of Manager, Business Development. In her current role, Zainab is responsible for managing CPDC’s diagnostics portfolio as well as supporting other licensing and investment opportunities.
Zainab has over 10 years of experience in radiopharmaceuticals having completed her PhD at McMaster University under Dr. John Valliant focusing on the discovery and development of small molecule- and nanoparticle-based radiopharmaceuticals. Prior to joining CPDC, Zainab worked as a Regulatory Consultant.
Uzair Sayani joined CPDC in June 2024 as the External Research Manager.
In his current role, Dr. Sayani manages CPDC’s current and future R&D radiopharmaceutical projects.
Uzair has over 6 years of experience in radiochemistry and molecular imaging, having completed his PhD at University of Ottawa under Dr. Benjamin Rotstein focusing on advancing key diagnostic and therapeutic radiotracers to improve patient outcomes.
Uzair has a Bachelor of Science from Brock University in Biotechnology. Prior to joining CPDC, Uzair worked as a translational radiochemist in a GMP manufacturing facility producing radiopharmaceuticals for use in clinical development.
Laurie Heynings joined CPDC in 2025 as an Accountant/Bookkeeper. Laurie has over 20 years of experience in various industries, including Non-Profit, Marketing, Construction and Manufacturing. As a member of the finance team, Laurie is responsible for day-to-day accounting functions. Laurie holds an Honours Bachelor of Arts from Brock University and an Honours Accounting diploma from Humber College.